Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer

CONCLUSIONS: These complete results from CONTROL show improved neratinib tolerability with proactive management at the start of therapy. Two-week neratinib DE with loperamide as needed was particularly effective.GOV REGISTRATION NUMBER: NCT02400476.PMID:36702070 | DOI:10.1016/j.breast.2022.12.003

Source: Breast - January 26, 2023 Category: Cancer & Oncology Authors: Arlene Chan Manuel Ruiz-Borrego Gavin Marx A Jo Chien Hope S Rugo Adam Brufsky Michael Thirlwell Maureen Trudeau Ron Bose Jos é A García-Sáenz Daniel Egle Barbara Pistilli Johanna Wassermann Kerry A Cheong Benjamin Schnappauf Dieter Semsek Christian F Source Type: research